Genetic variation in angiotensin II type 2 receptor gene influences extent of left ventricular hypertrophy in hypertrophic cardiomyopathy independent of blood pressure

被引:13
作者
Carstens, Nadia [1 ]
van der Merwe, Lize [2 ,3 ]
Revera, Miriam [4 ]
Heradien, Marshall [5 ]
Goosen, Althea [5 ]
Brink, Paul A. [5 ]
Moolman-Smook, Johanna C. [1 ]
机构
[1] Univ Stellenbosch, MRC Ctr Mol & Cellular Biol, Fac Hlth Sci, Dept Biomed Sci, ZA-7505 Tygerberg, South Africa
[2] Med Res Council South Africa, Biostat Unit, Tygerberg, South Africa
[3] Univ Western Cape, Dept Stat, ZA-7535 Bellville, South Africa
[4] IRCCS San Matteo Hosp, Dept Cardiol, Pavia, Italy
[5] Univ Stellenbosch, Dept Med, Fac Hlth Sci, ZA-7505 Tygerberg, South Africa
基金
英国惠康基金; 新加坡国家研究基金会;
关键词
Angiotensin II type 2 receptor; cardiac hypertrophy; hypertrophic cardiomyopathy; renin-angiotensin-aldosterone system; END-POINT REDUCTION; LOSARTAN INTERVENTION; ALDOSTERONE SYSTEM; POLYMORPHISMS; MASS; HYPERTENSION; EXPRESSION; MUTATIONS; BLOCKADE; DISTINCT;
D O I
10.1177/1470320310390725
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Introduction. Hypertrophic cardiomyopathy (HCM), an inherited primary cardiac disorder mostly caused by defective sarcomeric proteins, serves as a model to investigate left ventricular hypertrophy (LVH). HCM manifests extreme variability in the degree and distribution of LVH, even in patients with the same causal mutation. Genes coding for renin-angiotensin-aldosterone system components have been studied as hypertrophy modifiers in HCM, with emphasis on the angiotensin (Ang) II type 1 receptor (AT(1)R). However, Ang II binding to Ang II type 2 receptors (AT(2)R) also has hypertrophy-modulating effects. Methods. We investigated the effect of the functional + 1675 G/A polymorphism (rs1403543) and additional single nucleotide polymorphisms in the 3' untranslated region of the AT(2)R gene (AGTR2) on a heritable composite hypertrophy score in an HCM family cohort in which HCM founder mutations segregate. Results. We find significant association between rs1403543 and hypertrophy, with each A allele decreasing the average wall thickness by similar to 0.5 mm, independent of the effects of the primary HCM causal mutation, blood pressure and other hypertrophy covariates (p = 0.020). Conclusion. This study therefore confirms a hypertrophy-modulating effect for AT2R also in HCM and implies that + 1675 G/A could potentially be used in a panel of markers that profile a genetic predisposition to LVH in HCM.
引用
收藏
页码:274 / 280
页数:7
相关论文
共 32 条
[1]   A general test of association for quantitative traits in nuclear families [J].
Abecasis, GR ;
Cardon, LR ;
Cookson, WOC .
AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 66 (01) :279-292
[2]   Genetic basis of hypertrophic cardiomyopathy: From bench to the clinics [J].
Alcalai, Ronny ;
Seidman, Jonathan G. ;
Seidman, Christine E. .
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2008, 19 (01) :104-110
[3]   Left ventricle mass index and the common, functional, X-linked angiotensin II type-2 receptor gene polymorphism (-1332 G/A) in patients with systemic hypertension [J].
Alfakih, K ;
Maqbool, A ;
Sivananthan, M ;
Walters, K ;
Bainbridge, G ;
Ridgway, J ;
Balmforth, AJ ;
Hall, AS .
HYPERTENSION, 2004, 43 (06) :1189-1194
[4]   MEASUREMENT OF LEFT-VENTRICULAR MASS IN HYPERTROPHIC CARDIOMYOPATHY USING MRI - COMPARISON WITH ECHOCARDIOGRAPHY [J].
ALLISON, JD ;
FLICKINGER, FW ;
WRIGHT, JC ;
FALLS, DG ;
PRISANT, LM ;
VONDOHLEN, TW ;
FRANK, MJ .
MAGNETIC RESONANCE IMAGING, 1993, 11 (03) :329-334
[5]   Angiotensin II type 2 receptor gene polymorphisms in cardiovascular disease [J].
Balmforth, Anthony J. .
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2010, 11 (01) :79-85
[6]   Haploview: analysis and visualization of LD and haplotype maps [J].
Barrett, JC ;
Fry, B ;
Maller, J ;
Daly, MJ .
BIOINFORMATICS, 2005, 21 (02) :263-265
[7]   Angiotensin II type 2 receptor blockade amplifies the early signals of cardiac growth response to angiotensin II in hypertrophied hearts [J].
Bartunek, J ;
Weinberg, EO ;
Tajima, M ;
Rohrbach, S ;
Lorell, BH .
CIRCULATION, 1999, 99 (01) :22-25
[8]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[9]   Angiotensin II type 2 receptors and cardiac hypertrophy in women with hypertrophic cardiomyopathy [J].
Deinum, J ;
van Gool, JMG ;
Kofflard, MJM ;
ten Cate, FJ ;
Danser, AHJ .
HYPERTENSION, 2001, 38 (06) :1278-1281
[10]  
Erdmann J, 2000, HUM MUTAT, V15